COQ2 nephropathy: a treatable cause of nephrotic syndrome in children

  • Michelle C. Starr
  • Irene J. Chang
  • Laura S. Finn
  • Angela Sun
  • Austin A. Larson
  • Jens Goebel
  • Coral Hanevold
  • Jenny Thies
  • Johan L. K. Van Hove
  • Sangeeta R. Hingorani
  • Christina Lam
Brief Report

Abstract

Background

Nephrotic syndrome can be caused by a subgroup of mitochondrial diseases classified as primary coenzyme Q10 (CoQ10) deficiency. Pathogenic COQ2 variants are a cause of primary CoQ10 deficiency and present with phenotypes ranging from isolated nephrotic syndrome to fatal multisystem disease.

Case-Diagnosis/Treatment

We report three pediatric patients with COQ2 variants presenting with nephrotic syndrome. Two of these patients had normal leukocyte CoQ10 levels prior to treatment. Pathologic findings varied from mesangial sclerosis to focal segmental glomerulosclerosis, with all patients having abnormal appearing mitochondria on kidney biopsy. In two of the three patients treated with CoQ10 supplementation, the nephrotic syndrome resolved; and at follow-up, both have normal renal function and stable proteinuria.

Conclusions

COQ2 nephropathy should be suspected in patients presenting with nephrotic syndrome, although less common than disease due to mutations in NPHS1, NPHS2, and WT1. The index of suspicion should remain high, and we suggest that providers consider genetic evaluation even in patients with normal leukocyte CoQ10 levels, as levels may be within normal range even with significant clinical disease. Early molecular diagnosis and specific treatment are essential in the management of this severe yet treatable condition.

Keywords

Nephrotic syndrome Coenzyme Q10 deficiency COQ2 nephropathy Mitochondrial proliferation in podocytes Kidney pathology Ubiquinone 

Notes

Acknowledgements

We would like to thank Dr. Carlos R. Ferreira at the National Institutes of Health for his contribution of expertise in CoQ10 deficiency-associated diseases and Dr. Mark Lovell at Colorado Children’s Hospital for his assistance with obtaining renal pathology. We would also like to thank the patients and families for their agreement to participate in our manuscript.

Support

This study was supported by the National Institutes of Health (5T32GM007454 to IC) and (T32DK007662 to MS).

Author’s contributions

MS, IC, and CL generated ideal for case report. MS, IC, AS, AL, JG, CH, JVH, SH, and CL all participated in the clinical care of these patients. LF reviewed the renal pathology for all cases, assisted with interpretation of findings, and provided images for publication. MS wrote the first draft of this paper. All authors discussed the results and implications, commented on the manuscript at all stages, and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

467_2018_3937_MOESM1_ESM.docx (31 kb)
Table S1 (DOCX 30.8 kb)
467_2018_3937_MOESM2_ESM.docx (14 kb)
Table S2 (DOCX 14.2 kb)
467_2018_3937_MOESM3_ESM.docx (20 kb)
Figure S1 (DOCX 20 kb)
467_2018_3937_MOESM4_ESM.docx (13 kb)
ESM 1 (DOCX 12 kb)

References

  1. 1.
    Eddy AA, Symons JM (2003) Nephrotic syndrome in childhood. Lancet 362:629–639CrossRefPubMedGoogle Scholar
  2. 2.
    Hinkes BG, Mucha B, Vlangos CN, Gbadegesin R, Liu J, Hasselbacher K, Hangan D, Ozaltin F, Zenker M, Hildebrandt F (2007) Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 119:e907–e919CrossRefPubMedGoogle Scholar
  3. 3.
    Dogra S, Kaskel F (2017) Steroid-resistant nephrotic syndrome: a persistent challenge for pediatric nephrology. Pediatr Nephrol 32:965–974CrossRefPubMedGoogle Scholar
  4. 4.
    Desbats MA, Lunardi G, Doimo M, Trevisson E, Salviati L (2015) Genetic bases and clinical manifestations of coenzyme Q10 (CoQ10) deficiency. J Inherit Metab Dis 38:145–156CrossRefPubMedGoogle Scholar
  5. 5.
    Doimo M, Desbats MA, Cerqua C, Cassina M, Trevisson E, Salviati L (2014) Genetics of coenzyme q10 deficiency. Mol Syndromol 5:156–162CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    O'Rourke B, Cortassa S, Aon MA (2005) Mitochondrial ion channels: gatekeepers of life and death. Physiology (Bethesda) 20:303–315Google Scholar
  7. 7.
    Emmanuele V, López LC, Berardo A, Naini A, Tadesse S, Wen B, D'Agostino E, Solomon M, DiMauro S, Quinzii C, Hirano M (2012) Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol 69:978–983CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Desbats MA, Vetro A, Limongelli I, Lunardi G, Casarin A, Doimo M, Spinazzi M, Angelini C, Cenacchi G, Burlina A, Rodriguez Hernandez MA, Chiandetti L, Clementi M, Trevisson E, Navas P, Zuffardi O, Salviati L (2015) Primary coenzyme Q10 deficiency presenting as fatal neonatal multiorgan failure. Eur J Hum Genet 23:1254–1258CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, Caridi G, Piemonte F, Montini G, Ghiggeri GM, Murer L, Barisoni L, Pastore A, Muda AO, Valente ML, Bertini E, Emma F (2007) COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 18:2773–2780CrossRefPubMedGoogle Scholar
  10. 10.
    Barisoni L, Madaio MP, Eraso M, Gasser DL, Nelson PJ (2005) The kd/kd mouse is a model of collapsing glomerulopathy. J Am Soc Nephrol 16:2847–2851CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Imasawa T, Rossignol R (2013) Podocyte energy metabolism and glomerular diseases. Int J Biochem Cell Biol 45:2109–2118CrossRefPubMedGoogle Scholar
  12. 12.
    Desbats MA, Morbidoni V, Silic-Benussi M, Doimo M, Ciminale V, Cassina M, Sacconi S, Hirano M, Basso G, Pierrel F, Navas P, Salviati L, Trevisson E (2016) The COQ2 genotype predicts the severity of coenzyme Q10 deficiency. Hum Mol Genet 25:4256–4265CrossRefPubMedGoogle Scholar
  13. 13.
    Mitsui J, Matsukawa T, Yasuda T, Ishiura H, Tsuji S (2016) Plasma coenzyme Q10 levels in patients with multiple system atrophy. JAMA Neurol 73:977–980CrossRefPubMedGoogle Scholar
  14. 14.
    Montini G, Malaventura C, Salviati L (2008) Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med 358:2849–2850CrossRefPubMedGoogle Scholar
  15. 15.
    Gbadegesin RA, Winn MP, Smoyer WE (2013) Genetic testing in nephrotic syndrome—challenges and opportunities. Nat Rev Nephrol 9:179–184CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© IPNA 2018

Authors and Affiliations

  • Michelle C. Starr
    • 1
  • Irene J. Chang
    • 2
  • Laura S. Finn
    • 3
  • Angela Sun
    • 4
  • Austin A. Larson
    • 5
  • Jens Goebel
    • 6
  • Coral Hanevold
    • 1
  • Jenny Thies
    • 4
  • Johan L. K. Van Hove
    • 5
  • Sangeeta R. Hingorani
    • 1
  • Christina Lam
    • 4
  1. 1.Department of Pediatrics, Division of NephrologySeattle Children’s Hospital and University of WashingtonSeattleUSA
  2. 2.Department of Medical GeneticsUniversity of Washington Medical CenterSeattleUSA
  3. 3.Department of PathologySeattle Children’s Hospital and University of WashingtonSeattleUSA
  4. 4.Department of Pediatrics, Division of Genetic MedicineSeattle Children’s Hospital and University of WashingtonSeattleUSA
  5. 5.Department of Pediatrics, Section of Clinical Genetics and MetabolismUniversity of ColoradoAuroraUSA
  6. 6.Department of Pediatrics, Section of NephrologyUniversity of ColoradoAuroraUSA

Personalised recommendations